Recruiting
Phase 3

Ticagrelor

Sponsor:

Montreal Heart Institute

Code:

NCT07257198

Conditions

NSTEMI - Non-ST Segment Elevation MI

STEMI (ST Elevation MI)

Myocardial Infarction

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ticagrelor + placebo

Ticagrelor + aspirin

Study Details

Brief summary:

In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.

Conditions

NSTEMI - Non-ST Segment Elevation MI

STEMI (ST Elevation MI)

Myocardial Infarction

Study ID

NCT07257198

Start date

Mar 3, 2026

Status verified date

Mar, 2026

Completion date

Jan 1, 2031

Anticipated

Primary completion date

Jan 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion criteria:

  • Age ≥18 years;
  • Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
  • Coronary angiogram performed;
  • Planned for medical management alone, without revascularization;
  • Willingness to participate and to attend study visits;
  • Expected life expectancy ≥12 months.

Exclusion criteria:

  • Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
  • Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
  • Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
  • Confirmed or suspected spontaneous coronary artery dissection;
  • Concomitant indication for chronic oral anticoagulant;
  • Concomitant non-coronary indication for dual antiplatelet therapy;
  • Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;
  • Previous hospitalization for MI, PCI, or CABG within 12 months;
  • Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;
  • Unsuitability for either randomization treatment, based on the judgement of the treating physician

Study Design

Enrollment

2570 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Ticagrelor monotherapy

Ticagrelor 90 mg orally twice daily + placebo orally once daily

active comparator: DAPT with ticagrelor and aspirin

Ticagrelor 90 mg orally twice daily + aspirin 80 mg orally once daily

Interventions

Ticagrelor + placebo

Ticagrelor 90 mg twice daily + placebo once daily

Ticagrelor + aspirin

Ticagrelor 90 mg twice daily + aspirin 80 mg once daily

Primary outcome measure

  • Bleeding [ Time Frame: From randomization to 12 months ]
  • Patient-oriented ischemic clinical endpoint [ Time Frame: From randomization to 12 months ]

Central Contacts and Locations

Central contacts

Guillaume Marquis-Gravel, MD

1-514-376-3330guillaume.marquis.gravel@umontreal.ca

Roseline Therrien

1-514-461-1300roseline.therrien@seriant.org

Locations

Montreal Heart Institute

Recruiting

Montreal, Quebec, Canada, H1Y2P3

Contacts

Guillaume Marquis-Gravel, MD

1-514-376-3330guillaume.marquis.gravel@umontreal.ca

Samara Bloom, Msc

1-514-376-3330samara.bloom@icm-mhi.org

More Information

Sponsor

Montreal Heart Institute

Last update posted

Mar 10, 2026

Last verified

Mar, 2026

Keywords

  • Dual antiplatelet therapy
  • NSTEMI
  • medical treatment
  • STEMI
  • aspirin
  • ticagrelor
  • bleeding
  • ischemic events
  • randomized trial
  • pragmatic trial
  • randomized controlled trial

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Montreal Heart Institute on 2026-03-10.